PDL Biopharma Receivables

PDL Biopharma (PDLI) currently reports a receivables of $6.6M as of September 2020. That compares with $76M in the prior-year period — down 91.4% year over year. Use the charts on this page to explore PDL Biopharma's receivables history and peer comparisons.

PDL Biopharma's receivables decreased from $76M to $6.6M — a 91.4% year-over-year decrease (period ending September 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PDL Biopharma reported $6.6M in receivables as of September 2020. That compares with $76M in the prior-year period — down 91.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $6.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PDL Biopharma, and consider following PDLI for alerts when major investors trade the stock.

PDL Biopharma is classified in the Healthcare sector. On receivables, it currently shows $6.6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PDLI with unrelated industries.